# Giles Day

> Giles Day built Distributed Bio through customer revenue and partnerships before starting again at Ability Biotherapeutics. His second act carries forward a practical conviction: the people around the table help determine what a company can become.

- **Role:** Co-Founder & CEO at Ability Biotherapeutics
- **Organizations:** Ability Biotherapeutics, Distributed Bio, Pfizer, Charles River Laboratories, Amplitude Ventures
- **Education:** MSc in Computational Biology, University of Manchester
- **Known for:** Co-founded and led Distributed Bio to its acquisition by Charles River Laboratories., Built Distributed Bio through product revenue and partnerships., Co-founded Ability and led it through its public launch and seed financing.

## Career timeline

- **Before Distributed Bio** — Spent 15 years at Pfizer, including leadership of informatics for its Biotherapeutics and Bioinnovation division.
- **2008** — Represented Pfizer’s Targets and Mechanisms Informatics Group in an Ingenuity partnership announcement.
- **2010** — Ability’s biography places Distributed Bio’s two-person starting team in 2010; a contemporaneous December 2010 news listing identifies Day as co-founder.
- **2011** — Listed as Distributed Bio managing director and a cloud bioinformatics conference speaker.
- **2018** — Distributed Bio entered an exclusive partnership with Charles River Laboratories.
- **2020** — Distributed Bio acquired by Charles River on December 31.
- **2021** — Amplitude Ventures reported his addition to its advisory board.
- **2023** — Ability launched publicly in December with Day as co-founder and CEO.
- **2024** — Ability completed an $18 million total seed round and announced a Mila partnership.
- **2025** — Ability appointed Angèle Maki to its board in June and as chief business officer in December.

## Achievements

- Co-founded and led Distributed Bio to its acquisition by Charles River Laboratories.
- Built Distributed Bio through product revenue and partnerships.
- Co-founded Ability and led it through its public launch and seed financing.

## Latest updates

- **2025-12** — As Ability CEO, welcomed Angèle Maki as chief business officer, responsible for global partnering and investor relationships.
- **2025-06** — Welcomed Angèle Maki to Ability’s board.
- **2025-04** — Discussed Ability’s announced plan to move to Inspire Bio Innovations in Montreal in 2026; completion is not established here.
- **2024-10** — Ability announced a partnership with Mila.

## Links

- Website: https://www.ability.bio/
- LinkedIn: https://www.linkedin.com/in/giles-day-711897/

---

Profile page: https://yespress.io/giles-day
Published by YesPress — https://yespress.io
Last updated: 2026-10-11